<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">

</head>

<body>

<div class="uk-container">
    <div class="chapter-header">
        <div class="header-title">
            <div>
                <img src="ic_chart.svg" width="16" height="16" class="ic_chapter_icon">
            </div>
            <p class="chapter-title">7. Recommended Regimens for Treatment of Adults and Children with Drug-Susceptible TB (Pulmonary TB)</p>
        </div>
        <p> <span class="view-in-chapter-highlight"> View in chapter → <span> <a href="5_treatment_of_current_(active)_disease_therapy__c__special_clinical_situations.html#table7"> Special Clinical Situations </a></p>
        <p class="last-updated"><i>Last Updated October 2025</i></p>
    </div>
    <hr>
    <div class="uk-overflow-auto"
         id="table_7_recommended_regimens_for_treatment_of_adults_and_children_with_drug_susceptible_tb_pulmonary_tb">
         <div class="uk-tabs-container">
            <ul class="tabs">
                <li><button class="tab-button active-option" onclick="switchTab(0, event)">Initial Phase</button></li>
                <li><button class="tab-button" onclick="switchTab(1, event)">Continuation Phase</button></li>
            </ul>
        </div>

        <div id="content0" class="option-content active-option">
            <h4 class="duration with-info-icon">Total Duration (Initial + Continuation): 6 months<span class="info-icon" data-tooltip="NOTE: Duration of therapy for patients with drug-susceptible TB should be extended to 9 months (31 weeks continuation phase, 39 weeks total) for patients who have cavitary pulmonary TB and remain sputum culture positive after 2 months of therapy.
Many experts would extend therapy to 9 months for all patients with HIV/TB, especially those slow to convert to negative cultures or not on effective HIV treatment." data-tooltip-position="tooltip-bottom-center">i</span></h4>

            <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th colspan="2">Drug</th>
                        <td colspan="2">Isoniazid + Pyridoxine (Vitamin B6) <span class="info-icon" data-tooltip="NOTE: 

Pyridoxine (Vitamin B6) 25–50 mg/daily should be added to all regimens that include isoniazid (INH) in adults to prevent development of INH-induced peripheral neuropathy.
For patients with pre-existing peripheral neuropathy, increase pyridoxine dose to 100 mg/day unless there is abnormal renal function.">i</span><br> <br>
                                        Rifampin
                                        Pyrazinamide <br>
                                        Ethambutol
                        </td>
                    </tr>
                    <tr>
                        <th colspan="2">Interval & Dose # </th>
                        <td colspan="2" >Daily DOT <span class="info-icon" data-tooltip="NOTE: Daily DOT = 5 days/week (Monday through Friday). Self administered doses (including those on weekends) will not be counted toward the total doses.">i</span> for 40 doses</td>
                    </tr>
                    <tr>
                        <th colspan="2">Minimal Duration</th>
                        <td colspan="2">8 weeks</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content1" class="option-content">
            <h4 class="duration with-info-icon">Total Duration (Initial + Continuation): 6 months<span class="info-icon" data-tooltip="NOTE:

Duration of therapy for patients with drug-susceptible TB should be extended to 9 months (31 weeks continuation phase, 39 weeks total) for patients who have cavitary pulmonary TB and remain sputum culture positive after 2 months of therapy.
Many experts would extend therapy to 9 months for all patients with HIV/TB, especially those slow to convert to negative cultures or not on effective HIV treatment."  data-tooltip-position="tooltip-bottom-center">i</span></h4>

                        <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th colspan="1">Regimen</th>
                        <td colspan="1">Regimen 1a <span class="info-icon" data-tooltip="NOTE: Regimen 1a is the preferred regimen for patients with newly diagnosed TB.">i</span></td>
                        <td colspan="1">Regimen 1b</td>
                    </tr>
                    <tr>
                        <th colspan="1">Drug</th>
                        <td colspan="">Isoniazid + <br> Pyridoxine (Vitamin B6) <span class="info-icon" data-tooltip="NOTE: 

Pyridoxine (Vitamin B6) 25–50 mg/daily should be added to all regimens that include isoniazid (INH) in adults to prevent development of INH-induced peripheral neuropathy.
For patients with pre-existing peripheral neuropathy, increase pyridoxine dose to 100 mg/day unless there is abnormal renal function.">i</span> <br>
                                        Rifampin </td>
                        <td colspan="1">Isoniazid + <br> Pyridoxine (Vitamin B6) <span class="info-icon" data-tooltip="NOTE:

Pyridoxine (Vitamin B6) 25–50 mg/daily should be added to all regimens that include isoniazid (INH) in adults to prevent development of INH-induced peripheral neuropathy.
For patients with pre-existing peripheral neuropathy, increase pyridoxine dose to 100 mg/day unless there is abnormal renal function."  data-tooltip-position="tooltip-left">i</span> <br>
                                        Rifampin</td>
                    </tr>
                    <tr>
                        <th colspan="1">Interval & Dose #</th>
                        <td colspan="1">Daily DOT <span class="info-icon" data-tooltip="NOTE: Daily DOT = 5 days/week (Monday through Friday). Self administered doses (including those on weekends) will not be counted toward the total doses.">i</span> for 90 doses</td>
                        <td colspan="1">Thrice weekly DOT for 54 doses</td>
                    </tr>
                    <tr>
                        <th colspan="1">Minimal Duration</th>
                        <td colspan="1">18 weeks</td>
                        <td colspan="1">18 weeks</td>
                    </tr>
                    <tr>
                        <th colspan="1">Comments</th>
                        <td colspan="1">Any regimen must given by DOT.</td>
                        <td colspan="1">Continue ethambutol until susceptibility to isoniazid and rifampin is demonstrated</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <p>Additional Note: <br>
            1. Split dosing should be avoided. <br>
            2. Refer to current drug reference or drug package insert for a complete list of adverse drug reactions and drug interaction.
        </p>
    </div>
</div>

</body>

<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>

</html>
